TG Therapeutics, Inc.
Clinical trials sponsored by TG Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study checks how much MS drug gets into breast milk Results expected Oct 2026 (estimated)
- MS patients may soon get a shot instead of an IV drip Results expected Oct 2026 (estimated) May already have reported ↗
- Could a single infusion of modified immune cells tame autoimmune attacks? Results expected Dec 2026 (estimated)
- New dosing strategy for MS drug ublituximab under study in 800-Patient trial Results expected Jan 2027 (estimated) May already have reported ↗
- MS drug delivery showdown: belly vs. thigh, pen vs. syringe Results expected Jul 2027 (estimated) May already have reported ↗